These BCL2 variants are polyclonal, arise during VEN therapy and reduce the affinity of BCL2 with the drug, establishing secondary resistance to VEN in AML, despite VEN dose escalation (81, 89). This evidence concerns the gene BCL2 and acute myeloid leukemia.